Otsuka subsidiary Taiho Pharmaceuticals earlier announced that the results of a Phase III, randomized, placebo-controlled, ...

Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, also ...

Shares of US clinical-stage biotech Apogee Therapeutics closed down 17.3% at $39.24 yesterday, despite announcing positive 16 ...

French biotech Nanobiotix’ (shares were up nearly 7% at 4.44 euros in early trading, after the company announced two important developments that aim to reinforce the global positioning of potential ...

Eli Lilly (NYSE: LLY) led the way in pharma M&A during June. The US pharma major announced two major deals in the month, both ...

The GPRC5D-directed therapies market is witnessing robust growth, driven by high unmet need in relapsed/refractory multiple ...

Actinogen Medical (ASX: ACW), an Australian biotech, announced that the 100th participant in its pivotal XanaMIA Phase ...

Japanese drugmaker Chugai Pharmaceutical has entered into a joint research and license agreement to develop novel therapies for age-related diseases with Singapore-based biotech Gero.

The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK ...

Swissmedic has introduced a fast-track review process for clinical trial applications, aiming to speed up access to ...

USA and UK-based KalVista Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Ekterly (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of ...

Austria’s HeartBeat.bio and biotx.ai have announced a strategic partnership to identify and validate novel therapeutic ...